Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.69 |
| ▸ | RAB9A | P51151 | 7/20 | 0.69 |
| ▸ | CA12 | O43570 | 1/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | CA9 | Q16790 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14771799 | 0.90 | NPC1 (0.62) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL9781781 | 0.88 | NPC1 (0.61) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL27705808 | 0.88 | NPC1 (0.61) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL295136 | 0.87 | NPC1 (0.69) | NPC1RAB9AALDH1A1EPHX2HDAC3 | |
| SCHEMBL7608732 | 0.87 | NPC1 (0.59) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL27537790 | 0.87 | NPC1 (0.59) | NPC1RAB9AALDH1A1EPHX2L3MBTL1 | |
| SCHEMBL690027 | 0.87 | NPC1 (0.59) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL28230418 | 0.85 | NPC1 (0.57) | NPC1RAB9ACA12CA1CA2 | |
| SCHEMBL693305 | 0.85 | NPC1 (0.67) | NPC1RAB9AALDH1A1EPHX2HDAC3 | |
| Hydrochloric Acid SCHEMBL28989899 | 0.85 | NPC1 (0.67) | NPC1RAB9AALDH1A1EPHX2HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3269717-B9 | POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND NXL104 | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-08-09 | — | — | EP | disclosed |
| EP-3269717-B2 | POLYMORPHIC AND PSEUDOPOLYMORPHIC FORMS OF PHARMACEUTICAL COMPOUND NXL104 | PFIZER IRELAND PHARMACEUTICALS (IE) | 2023-06-14 | — | — | EP | disclosed |
| CN-109824668-A | The polymorphic forms and pseudopolymorphic forms of medical compounds | 辉瑞爱尔兰制药公司 | 2019-05-31 | — | — | CN | disclosed |
| US-20170210742-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD (BM) | 2017-07-27 | — | — | US | disclosed |
| US-9580424-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2017-02-28 | — | — | US | disclosed |
| CN-102834395-B | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | 阿斯利康控股法国有限公司 | 2016-06-29 | — | — | CN | disclosed |
| US-20150246920-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-09-03 | — | — | US | disclosed |
| US-9062053-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-Diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2015-06-23 | — | — | US | disclosed |
| CN-104592229-A | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | ASTRA ZENECA HOLDING FRANCE SAS | 2015-05-06 | — | — | CN | disclosed |
| US-20140349967-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2014-11-27 | — | — | US | disclosed |
| US-8835455-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2014-09-16 | — | — | US | disclosed |
| US-20130267480-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-10-10 | — | — | US | disclosed |
| US-8471025-B2 | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt | ALLERGAN PHARMACEUTICALS INTERNATIONAL LIMITED (IE) | 2013-06-25 | — | — | US | disclosed |
| CN-102834395-A | Polymorphic and pseudopolymorphic forms of a pharmaceutical compound | NOVEXEL SA | 2012-12-19 | — | — | CN | disclosed |
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | FOREST LABORATORIES HOLDINGS LTD. (BM) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152311-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | NPC1 3027/4885RAB9A 2273/4885CA12 576/4885 |
| US-20130267480-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | NPC1 3027/4885RAB9A 2273/4885CA12 576/4885 |
| US-20170210742-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | NPC1 3027/4885RAB9A 2273/4885CA12 576/4885 |
| US-20140349967-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | NPC1 3027/4885RAB9A 2273/4885CA12 576/4885 |
| US-20150246920-A1 | NOVEL CRYSTALLINE FORMS OF TRANS-7-OXO-6-(SULPHOOXY)-1,6-DIAZABICYCLO[3,2,1]OCTANE-2-CARBOXAMIDE SODIUM SALT | SLC10A6, SLC5A2, SLC5A1 | NPC1 3027/4885RAB9A 2273/4885CA12 576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.